Arthur v. Dunn
195 F. Supp. 3d 1257
M.D. Ala.2016Background
- Plaintiff Tommy Arthur, a death-row inmate, challenged Alabama’s three-drug lethal-injection protocol (midazolam, rocuronium/pancuronium, potassium chloride) under § 1983 as both a facial and as-applied Eighth Amendment claim. The case began in 2011 and the court conducted a bifurcated bench trial in Jan. 2016 on the facial claim and consciousness-assessment equal-protection claim.
- In April 2016 the court rejected Arthur’s facial challenge for failure to identify a known, available alternative; remaining was Arthur’s as-applied claim based on alleged idiosyncratic medical conditions (chiefly probable coronary artery disease and risk of paradoxical midazolam reaction).
- The court ordered the parties to attempt to stipulate a modified protocol tailored to Arthur’s medical concerns; Arthur’s proposed modifications were vague (e.g., “gradual” midazolam, unspecified monitoring and medications). Defendants maintained that the existing protocol (500 mg midazolam bolus) was adequate.
- Arthur relied chiefly on cardiologist J. Russell Strader, Jr., M.D., who opined Arthur likely has clinically significant obstructive CAD and that midazolam’s hemodynamic effects could produce ischemia/MI before sedation at clinical-dose extrapolation; Arthur’s anesthesiology evidence (Alan Kaye, M.D., Ph.D.) largely disclaimed midazolam as suitable for executions.
- Arthur refused up-to-date cardiac testing and has not seen a cardiologist since 2009; experts therefore relied on old records and extrapolation from clinical midazolam doses (2–5 mg) rather than any empirical evidence about a 500 mg bolus used in executions.
- Defendants moved for judgment on the pleadings or summary judgment as to the as-applied claim; the court treated the motion as for summary judgment and granted it. Arthur’s motion for a new trial (Rule 59) based on post-trial testimony suggesting compounded pentobarbital might be obtainable was denied as not likely to produce a different result.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether an as-applied Eighth Amendment method-of-execution claim may proceed without identifying a known, available alternative | Arthur argued his unique medical condition (probable CAD; age/anxiety) creates a high likelihood of severe pain unless the protocol is modified (e.g., gradual midazolam with monitoring) | Defendants argued Glossip/Baze require a known, available alternative for both facial and as-applied claims; Arthur failed to propose a concrete, implementable alternative | Court held Glossip/Baze (and Eleventh Circuit precedent) require a known, available alternative for as-applied claims and Arthur failed that requirement; claim dismissed |
| Whether Arthur proved a substantial, imminent risk that midazolam will cause severe pain (heart attack before sedation) when applied to him | Arthur relied on Dr. Strader: probable obstructive CAD and extrapolated hemodynamic effects of midazolam will precede sedation producing ischemia/MI and severe pain | Defendants pointed to lack of recent cardiac evaluation, speculative extrapolation from small clinical doses to a 500 mg bolus, and contrary aspects of record (including Arthur’s own anesthesiology evidence) | Court held Arthur did not present reliable, non‑speculative evidence that severe pain was “sure or very likely”; risk prong not met |
| Whether Arthur’s proposed protocol modifications were sufficiently specific, feasible, and readily implemented | Arthur proposed gradual administration, monitoring (EEG, EKG, BIS), trained personnel, and adjunct meds—arguing these would reduce risk | Defendants argued proposals were vague, medically framed (not formulated as implementable execution procedures), and inconsistent with Arthur’s own anesthesiology expert who rejected midazolam | Court found Arthur’s proposals too vague and marginal, and inconsistent with his own evidence; they did not constitute a viable alternative under Baze/Glossip |
| Whether newly discovered testimony (Dr. Buffington) warranted a new trial on availability of pentobarbital | Arthur claimed post-trial testimony suggested pharmacists might compound pentobarbital, undermining prior finding that pentobarbital is unavailable | Defendants produced Buffington affidavit showing he contacted pharmacists and none were willing/able to supply compounded pentobarbital | Court denied new trial: Buffington’s testimony was speculative and post-deposition affidavit confirmed pentobarbital was not available; new evidence would not likely change result |
Key Cases Cited
- Baze v. Kentucky, 553 U.S. 35 (establishes risk + known, available alternative test for method‑of‑execution Eighth Amendment claims)
- Glossip v. Gross, 135 S. Ct. 2726 (reaffirmed Baze; requires prisoner to identify feasible, readily implemented alternative that significantly reduces substantial risk)
- Gissendaner v. Comm’r, Ga. Dep’t of Corr., 803 F.3d 565 (11th Cir.) (as-applied challenges must meet Baze/Glossip pleading and proof requirements)
- Bucklew v. Lombardi, 783 F.3d 1120 (8th Cir. 2015) (as-applied challenge must identify feasible, readily implemented alternative that significantly reduces risk)
- Daubert v. Merrell Dow Pharm., 509 U.S. 579 (governs admissibility/reliability of expert testimony)